I have been following AEMD for a long time. The broad spectrum capabilities of the HP are well known to long term followers of this stock. However all these years we had something similar to small or individual case studies of the HP with different applications. Now finally, we are seeing results (albeit partial) of what the medical community/FDA likes to see - a clinical trial. The results are better then what I had expected. This PR is loaded with some strong info. e.g. 3 patients have an undetectable viral load after 48 weeks! If this is going to be reflective of the future with more patients, then it would be interesting to see what steps JJ takes. I say this because if this were the results of a drug trial the valuation of AEMD would be in hundreds of millions already if not billions. I may be wrong but I do not think that there has been a drug in the HCV field which has given such results. If the HP was a drug, AEMD would have been an attractive partnership/takeover candidate for major pharmas. But the HP concept is new in medicine and that may make the medical community a bit wary and suspicious. Also, I think the fact that usually HCV is treated by Gastroenterologists and not kidney doctors, is the biggest obstacle to the HP. The renal doctors may embrace it without problems but to get patients for treatments they still need referals from other MDs like primary care doctors. So, this may involve education of a lot of the medical community which can be a daunting task for a small setup like AEMD.
I think there are 2 answers to this - either the Govt. or a big dialysis company or even better both!
With the current trends to curtail healthcare costs, which is being encouraged by the govt. and insurance companies, the HP should be a no brainer. The main step would be to expose it to the correct people. A better and more financially sound option would be if a major dialysis co. sees the potential of the HP and teams up with AEMD. With their already existing infrastructure and financial backing AEMD would reap rewards immediately.
In the next few months we should hear a lot more from AEMD about the HP with regards to HCV and Sepsis.